Zydus Cadila acquires six brands from MSD

29 Dec 2016 Evaluate

Zydus Cadila, through its wholly-owned subsidiary Zydus Healthcare, has acquired six brands from global pharma major MSD and its subsidiaries. The brands include Deca-durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range, which fall in the men’s health, women’s health, cardiovascular and wound management therapy segments. The deal includes transfer of distribution and commercialization rights and assignment of trademarks of all the six brands to Zydus Healthcare in India.

As part of the deal, Organon (India), one of the legal subsidiaries through which MSD operates its business in India, has also transferred the distribution and commercialization rights for Deca-Durabolin and Durabolin to Zydus for Nepal.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.


Zydus Lifesciences Share Price

1042.30 37.65 (3.75%)
05-Jun-2024 10:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1475.95
Dr. Reddys Lab 5877.00
Cipla 1505.55
Zydus Lifesciences 1042.30
Lupin 1622.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.